PAX2 distinguishes benign mesonephric and mullerian glandular lesions of the cervix from endocervical adenocarcinoma, including minimal deviation adenocarcinoma

American Journal of Surgical Pathology

Volumn 34, Issue 2, 2010, Pages 137-146

  Rabban, Joseph T ^a   McAlhany, Stephanie ^a   Lerwill, Melinda F ^b   Grenert, James P ^a   Zaloudek, Charles J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Adenoma malignum; Endocervical adenocarcinoma; Mesonephric hyperplasia; Mesonephric remnants; Minimal deviation adenocarcinoma; PAX2

Indexed keywords

PAX2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR PAX2; TUMOR MARKER;

ADENOCARCINOMA; ADENOMA; ARTICLE; CANCER STAGING; CELL NUCLEUS; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; MESONEPHROS; METABOLISM; METHODOLOGY; MUELLERIAN DUCT; PATHOLOGY; PRECANCER; UTERINE CERVIX; UTERINE CERVIX TUMOR;

ADENOCARCINOMA; ADENOMA; CELL NUCLEUS; CERVIX UTERI; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; MESONEPHROS; MULLERIAN DUCTS; NEOPLASM STAGING; PAX2 TRANSCRIPTION FACTOR; PRECANCEROUS CONDITIONS; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 75649093752     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3181c89c98     Document Type: Article

References (24)

1. Amin-Hanjani S, Paulson J, Henien S, et al. Mesonephric rest hyperplasia. A potential diagnostic pitfall. Arch Pathol Lab Med. 1991;115:1059-1061.
2. Bowen NJ, Logani S, Dickerson EB, et al. Emerging roles for PAX8 in ovarian cancer and endosalpingeal development. Gynecol Oncol. 2007;104:331-337.
3. Cao D, Gown AM, Vang RS, et al. Expression of PAX2 in endometrial hyperplasia and carcinomas: immunohistochemical analysis of 136 cases. Mod Pathol. 2007;20(suppl 2):191A.
4. Daniel L, Lechevallier E, Giorgi R, et al. Pax-2 expression in adult renal tumors. Hum Pathol. 2001;32:282-287.
5. Dressler GR, Douglass EC. Pax-2 is a DNA-binding protein expressed in embryonic kidney and Wilms tumor. Proc Natl Acad Sci USA. 1992;89:1179-1183.
6. Ferry JA, Scully RE. Mesonephric remnants, hyperplasia, and neo-plasia in the uterine cervix. A study of 49 cases. Am J Surg Pathol. 1990;14:1100-1111.
7. Fickenscher HR, Chalepakis G, Gruss P. Murine Pax-2 protein is a sequence-specific trans-activator with expression in the genital system. DNA Cell Biol. 1993;12:381-391.
8. Gilks CB, Young RH, Aguirre P, et al. Adenoma malignum (minimal deviation adenocarcinoma) of the uterine cervix. A clinico-pathological and immunohistochemical analysis of 26 cases. Am J Surg Pathol. 1989;13:717-729.
9. Gruss P, Walther C. Pax in development. Cell. 1992;69:719-722.
10. Jones MA, Andrews J, Tarraza HM. Mesonephric remnant hyper-plasia of the cervix: a clinicopathologic analysis of 14 cases. Gynecol Oncol. 1993;49:41-47.
11. Lang D, Powell SK, Plummer RS, et al. PAX genes: roles in development, pathophysiology, and cancer. Biochem Pharmacol. 2007;73:1-14.
12. McCluggage WG, Oliva E, Herrington CS, et al. CD10 and calre-tinin staining of endocervical glandular lesions, endocervical stroma and endometrioid adenocarcinomas of the uterine corpus: CD10 positivity is characteristic of, but not specific for, mesonephric lesions and is not specific for endometrial stroma. Histopathology. 2003;43:144-150.
13. Nonaka D, Chiriboga L, Soslow RA. Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas. Am J Surg Pathol. 2008;32:1566-1571.
14. Ordi J, Nogales FF, Palacin A, et al. Mesonephric adenocarcinoma of the uterine corpus: CD10 expression as evidence of mesonephric differentiation. Am J Surg Pathol. 2001;25:1540-1545.
15. Ordi J, Romagosa C, Tavassoli FA, et al. CD10 expression in epithelial tissues and tumors of the gynecologic tract: a useful marker in the diagnosis of mesonephric, trophoblastic, and clear cell tumors. Am J Surg Pathol. 2003;27:178-186.
16. Seidman JD, Tavassoli FA. Mesonephric hyperplasia of the uterine cervix: a clinicopathologic study of 51 cases. Int J Gynecol Pathol. 1995;14:293-299.
17. Silver SA, Devouassoux-Shisheboran M, Mezzetti TP, et al. Meso-nephric adenocarcinomas of the uterine cervix: a study of 11 cases with immunohistochemical findings. Am J Surg Pathol. 2001;25: 379-387.
18. Steeper TA, Wick MR. Minimal deviation adenocarcinoma of the uterine cervix ("adenoma malignum"). An immunohisto-chemical comparison with microglandular endocervical hyperplasia and conventional endocervical adenocarcinoma. Cancer. 1986;58: 1131-1138.
19. Toki T, Zhai YL, Park JS, et al. Infrequent occurrence of high-risk human papillomavirus and of p53 mutation in minimal deviation adenocarcinoma of the cervix. Int J Gynecol Pathol. 1999;18: 215-219.
20. Tong GX, Melamed J, Mansukhani M, et al. PAX2: a reliable marker for nephrogenic adenoma. Mod Pathol. 2006;19:356-363.
21. Tong GX, Chiriboga L, Hamele-Bena D, et al. Expression of PAX2 in papillary serous carcinoma of the ovary: immunohistochemical evidence of fallopian tube or secondary Mullerian system origin? Mod Pathol. 2007;20:856-863.
22. Torres M, Gomez-Pardo E, Dressler GR, et al. Pax-2 controls multiple steps of urogenital development. Development. 1995;121:4057-4065.
23. Truskinovksy AM, Stelow EB, Jessurun J. Staining for p16 of cervical mesonephric remnants and hyperplasia: a potential diagnostic pitfall. Mod Pathol. 2006;19:925(A).
24. Wu H, Chen Y, Liang J, et al. Hypomethylation-linked activation of PAX2 mediates tamoxifen-stimulated endometrial carcinogenesis. Nature. 2005;438:981-987.